The Long Game: A Functional Cure Is Possible with Nucleoside Analogues and the Tincture of Time

Authors

Nicholas Noverati, Thomas Jefferson UniversityFollow
Vivian Yan, Thomas Jefferson UniversityFollow
Jay Jun, Thomas Jefferson UniversityFollow
Dina Halegoua-De Marzio, Thomas Jefferson UniversityFollow
Hie-Won Hann, Thomas Jefferson UniversityFollow

Document Type

Article

Publication Date

7-4-2023

Comments

This article is the author's final published version in Livers, Volume 3, Issue 3, 2023, Pages 325 - 330.

The published version is available at https://doi.org/10.3390/livers3030024.

Copyright © 2023 by the authors.

Abstract

Chronic hepatitis B is still prevalent globally. Many patients are treated for many years with nucleos(t)ide analogues to prevent the virus from actively replicating. However, although it typically requires consecutive treatment for more than 10 years, patients can achieve a functional cure from this virus. This case series presents details of functional cures in patients who received varying nucleos(t)ide therapies for an average of 15.3 years before losses of hepatitis B surface antigen and viral load were observed. It is imperative to understand that abbreviating therapy once a functional cure is achieved may be a possibility in treating patients in order to limit the associated costs and side effects of an otherwise lifelong therapy until other cure drugs are approved.

Recommended Citation

Noverati, Nicholas; Yan, Vivian; Jun, Jay; Halegoua-De Marzio, Dina; and Hann, Hie-Won, "The Long Game: A Functional Cure Is Possible with Nucleoside Analogues and the Tincture of Time" (2023). Division of Gastroenterology and Hepatology Faculty Papers. Paper 92.
https://jdc.jefferson.edu/gastro_hepfp/92

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 License.

Language

English